Related Experiment Video

Updated: May 19, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Ta1722, an anti-angiogenesis inhibitor targeted on VEGFR-2 against human hepatoma

Lei Zheng1, Xu He, Weina Ma

  • 1School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi Province, PR China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|August 3, 2012
PubMed

Insights

Ta1722, a novel taspine derivative, effectively inhibits cell proliferation and angiogenesis. This compound shows promise as an anti-angiogenesis agent by targeting the VEGF/VEGFR-2 pathway.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cancer Research

Background:

  • Angiogenesis is crucial for tumor growth and metastasis.
  • Targeting angiogenesis is a key strategy in cancer therapy.
  • Novel compounds with anti-angiogenic properties are needed.

Purpose of the Study:

  • To investigate the anti-angiogenesis potential of Ta1722, a novel taspine derivative.
  • To elucidate the mechanisms underlying Ta1722's anti-angiogenic effects.
  • To evaluate Ta1722's efficacy in inhibiting tumor growth in vivo.

Main Methods:

  • In vitro studies: MTT assays for cell proliferation on human cell lines (SMMC-7721, A549, MCF-7, Lovo, ECV304).
  • In vitro angiogenesis assays: Chick embryo chorioallantoic membrane (CAM) angiogenesis and tube formation assays.
  • Molecular analysis: Western blotting and RT-PCR to determine protein and mRNA expression of angiogenesis-related factors.
  • In vivo studies: SMMC-7721 nude mouse xenotransplant model to assess tumor growth inhibition.

Main Results:

  • Ta1722 demonstrated significant inhibition of cell proliferation across multiple human cancer cell lines.
  • Ta1722 effectively suppressed angiogenesis in CAM assays and inhibited tube formation in vitro.
  • Ta1722 downregulated the expression of key pro-angiogenic proteins and their corresponding mRNA.
  • In vivo, Ta1722 significantly inhibited tumor growth in the SMMC-7721 nude mouse xenotransplant model.

Conclusions:

  • Ta1722 exhibits potent anti-angiogenesis and anti-proliferative activities.
  • The anti-angiogenic effects of Ta1722 are mediated through the interruption of the VEGF/VEGFR-2 pathway.
  • Ta1722 represents a promising therapeutic candidate for angiogenesis inhibition in cancer treatment.

More Related Videos

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis10:56

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis

Published on: August 1, 2019

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...